By The Life Science Report

Source: Streetwise Reports   03/27/2019

This clinical decision support software integration is the first of its kind, according to the company.

Canada-based Premier Health Group Inc. (PHGI:CSE; PHGRF:OTCQB; 6PH:FSE), a company focused on “developing innovative approaches that combine human skill-based expertise with emerging technologies for the healthcare industry,” announced that it has initiated the integration of CB2 Insights’ (CBII:CSE) medical cannabis Clinical Decision Support (CDS) tool into its Juno Electronic Medical Records (EMR) platform.

More than 4,600 physicians and healthcare practitioners will have access to the industry’s only medical cannabis specific CDS tool, and will help them incorporate medical cannabis into their patients’ treatment plans, the company stated.

“This first-of-its-kind integration in the medical cannabis sector will allow physicians and healthcare practitioners to overcome many of the barriers they face from a lack of access to medical cannabis education, qualification factors, risks and benefits of cannabinoid therapy, all on a patient-specific basis using clinically validated data,” Premier Health noted.

CB2 Insights, through its clinical arm in the U.S., operates 28 medical cannabis evaluation centers “to study and understand the clinical outcomes of cannabinoid therapy.”

“We are now in a position to benefit from the aggregated and anonymized data gathered from over 300,000 patient visits in a clinical environment to power our CDS tool that will bring clinicians a point-of-care application to help them incorporate cannabis into their practice and create improved access for patients who can benefit from cannabinoid therapy,” Prad Sekar, CB2’s CEO, stated.

“This is pretty revolutionary,” Dr. Essam Hamza, CEO of Premier Health, told Streetwise Reports. “Doctors really don’t understand how to prescribe medical cannabis; they’ve never been taught in medical school. They have been taught to go with evidence-based treatments, but they don’t know where to find the evidence on medical cannabis. Integrating the CDS tool into our platform changes the landscape to fill that knowledge gap.”

“The clinically led, evidence-based data will embed right into our EMR software to help guide the doctor to the correct medical cannabis product and dosing based on parameters such as the patient’s medical condition, age and sex,” Dr. Hamza added.

“This agreement with CB2 will provide us a robust, validated tool to give our physicians and healthcare practitioners a safe and secure way to qualify, educate and where appropriate, prescribe medical cannabis to their patients in a compliant manner,” Dr. Hamza explained.

Premier Health, through its subsidiary Cloud Practice, is developing “proprietary technology to deliver quality healthcare through the combination of connected primary care clinics with telemedicine and artificial intelligence (AI).” It has an ecosystem of 290 clinics in Canada with nearly 3 million registered patients.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Disclosure:
1) Patrice Fusillo compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees. As of the date of this article, an affiliate of Streetwise Reports has a consulting relationship with Premier Health Group Inc. Please click here for more information.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Premier Health Group Inc., a company mentioned in this article.

( Companies Mentioned: PHGI:CSE; PHGRF:OTCQB; 6PH:FSE,
)